Increasing the liver donation pool: Eculizumab desensitization for ABO-incompatible living donor liver transplantation – A case series
ECU-based complement inhibition may offer a simplified, potentially AMR-reducing approach in ABO-I LDLT; these findings are preliminary and hypothesis-generating, requiring validation in larger studies.
Authors
- B. Valdepenas
- Jamie Benken (ORCID: https://orcid.org/0000-0003-2588-2356)
- Hojung Kim (ORCID: https://orcid.org/0000-0002-2713-4207)
- Ivo Tzvetanov (ORCID: https://orcid.org/0000-0002-6496-4728)
- Sujata Gaitonde (ORCID: https://orcid.org/0000-0002-8663-5749)
- Mario Spaggiari
- Amaan Chalisa
- E. Kortan
- Enrico Benedetti (ORCID: https://orcid.org/0000-0003-1120-6058)
- María J. T. de Alaniz
- Luke G Atia
Institutions
- University of Illinois Chicago (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
Publication Details
- Journal
- Human Immunology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1016/j.humimm.2025.111637
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00